Objectives: No study to clarify which inflammation score could best reflect survival in a cohort of metastatic breast cancer (mBC) patients who received everolimus plus exemestane. Methods: The impact of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) on PFS and OS was evaluated. Results: A total of 80 mBC patients were included. Median PFS was 8.9 months and median overall survival (OS) was 31.8 months. We found that there was no significant difference between NLR, PLR, SII, and PNI groups for median PFS and OS. Conclusion: Inflammation-based prognostic scores were not correlated with prognosis in patients with mBC who had been treated with everolimus plus exemestane. Keywords: Everolimus; breast cancer; systemic inflammation-based prognostic scores; biomarkers.
Corresponding Author: Emir Celik